Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
13.3M
-
Shares change
-
+53.6K
-
Total reported value, excl. options
-
$24M
-
Value change
-
+$170K
-
Number of buys
-
11
-
Number of sells
-
-15
-
Price
-
$1.80
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q2 2023
48 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q2 2023.
NextCure, Inc. - Common Stock (NXTC) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.3M shares
of 28M outstanding shares and own 47.52% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2.71M shares), Sofinnova Investments, Inc. (2.67M shares), MILLENNIUM MANAGEMENT LLC (1.41M shares), BlackRock Inc. (925K shares), VANGUARD GROUP INC (908K shares), Long Focus Capital Management, LLC (556K shares), ACADIAN ASSET MANAGEMENT LLC (488K shares), TANG CAPITAL MANAGEMENT LLC (400K shares), CITADEL ADVISORS LLC (393K shares), and FEDERATED HERMES, INC. (367K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.